InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Blanchard Cheryl R, Présidente et Directrice Générale. Insider active across 3 companies, notably Anika Therapeutics, Inc.. In total, 16 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €99k. History available since 15 June 2021. The latest transaction was disclosed on 22 May 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Blanchard Cheryl R
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
24,519 sharesCommon StockSEC:0001193125-26-111494:0
20,001 sharesCommon StockSEC:0001193125-26-102239:0
5,000 sharesCommon StockSEC:0000950170-25-102476:0
5,000 shares0Common StockSEC:0000950170-25-077268:0
25,132 shares0Common StockSEC:0001171843-25-001531:0
30,060 shares0Common StockSEC:0001171843-25-001467:0
5,871 shares@ US$16.6252.1% of flowCommon StockSEC:0001171843-25-001404:1
20,002 shares0Common StockSEC:0001171843-25-001404:0
14,420 shares0Common StockSEC:0001171843-24-001307:0
24,575 shares0Common StockSEC:0001171843-23-002685:0
30,060 shares0Common StockSEC:0001171843-23-001684:0
14,419 shares0Common StockSEC:0001171843-23-001595:0
24,576 shares0Common StockSEC:0001171843-22-002980:0
4,287 shares@ US$25.35954.5% of flowCommon StockSEC:0001171843-22-001833:0
Canonical exit: 9 Jun 2022 (T+90)
14,420 shares0Common StockSEC:0001171843-22-001809:0
2,994 shares@ US$33.4045.5% of flowCommon StockSEC:0001171843-21-004397:0
16 of 16 declarations
About Blanchard Cheryl R
Cheryl R Blanchard is President and Chief Executive Officer. She has 16 filings in total, and across the sampled recent filings from 2021-06-17 to 2026-03-17, buys total EUR 98706 and sells EUR 0, with the most common transaction nature shown as option exercise. Her filings concern Anika Therapeutics, Inc. and Vigil Neuroscience, Inc.
